Physician profile
Timothy Kowaleski
NPI 1083093272
$15,415.96
in general payments reported to CMS, 2019-2025
23 companies · $13K in 2025
The $13K reported for 2025 was more than what 97% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $449 · 2023: $267 · 2024: $1,396 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,280 · Food and Beverage: $3,507 · Travel and Lodging: $1,793 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,280.00 |
| Food and Beverage | $3,507.30 |
| Travel and Lodging | $1,793.48 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $11,267.87 | 2021-2025 | Vivitrol, Aristada, Lybalvi |
| Abbvie INC. | $839.79 | 2021-2025 | |
| Lundbeck LLC | $790.99 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $395.50 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $298.62 | 2021-2022 | |
| Axsome Therapeutics, INC. | $263.82 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $226.48 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $214.08 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.45 | 2021-2025 | Caplyta |
| Corium, LLC | $160.39 | 2022-2025 | Azstarys |
| Indivior INC. | $148.64 | 2021-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $115.20 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $101.13 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $83.91 | 2024-2025 | Cobenfy |
| Orexo US, INC. | $77.63 | 2024-2025 | Zubsolv |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $75.58 | 2024-2025 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $66.00 | 2021-2024 | Uzedy |
| Gilead Sciences, INC. | $22.84 | 2024 | |
| Collegium Pharmaceutical, INC. | $21.34 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $18.14 | 2022 | |
| Tris Pharma INC | $15.00 | 2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $12.77 | 2022 | |
| Eisai INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kowaleski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.